We represented Altaris Capital Partners, a healthcare investment firm with an exclusive focus on building companies that deliver innovation and efficiency to the healthcare system, in their acquisition of Meridian Medical Technologies, a global leader in emergency response and health security solutions with a focus on complex drug-device combination products, from Pfizer Inc. (NYSE:PFE). Terms of the transaction were not disclosed.
The team was led by Bass, Berry & Sims attorney Ryan Thomas and included corporate attorneys Scott Bell, Brad Hart and Brad Yenter.
We are grateful for the opportunity to represent Altaris in this transaction, which continues to build upon our firm’s experience in private equity-back deals in the healthcare space,” said Thomas.
The transaction was highlighted in several media outlets, including:
“Altaris Announces Acquisition of Meridian Medical Technologies from Pfizer,” Altaris (November 2, 2021)
“Atlaris to buy Meridian from Pfizer,” PE Hub (November 2, 2021)
“Altaris Capital Acquires Meridian Medical,” Medical Finance News (November 2, 2021)
“Altaris Capital Partners’ Acquisition of Meridian Medical Technologies,” Global Legal Chronicle (November 5, 2021)
Altaris is a healthcare investment firm with an exclusive focus on building companies that deliver innovation and efficiency to the healthcare system. Altaris’ operating companies seek to address some of the most complex problems in the healthcare industry, with the ultimate goal of improving access and quality of life for patients. Since inception in 2003, Altaris has invested in more than 40 healthcare companies that have contributed to advancements in the industry and generated significant value appreciation for investors. Altaris is headquartered in New York City and currently manages $6.0 billion of equity capital.
Bass, Berry & Sims has significant experience representing buyers and sellers in both public and private company strategic transactions, as well as extensive familiarity in structuring private equity acquisitions and financings. We have served as counsel to national, major middle-market private equity funds and portfolio companies in more than 100 transactions across a myriad of industries in the last two years. Our work has earned the firm recognition in national industry leading league tables and other outlets, including being ranked as #20 Most Active in U.S. Private Equity and #4 Most Active in Healthcare PE (Q2 Rankings, Pitchbook). Additionally, our team was honored by The M&A Advisor with several awards in the last five years, most recently with the Healthcare & Life Sciences Deal of the Year (Over $1B) and Corporate/Strategic Deal of the Year (Over $1B) in 2020. To learn more about our team, industry experience and value-add, click here.